50419-88-0

Usage

Uses

Used in Chemical Industry:
BUTTPARK 80\07-66 is used as a corrosion inhibitor for protecting metal surfaces from oxidation and corrosion, particularly in aqueous environments. Its application helps to extend the life of metal equipment and reduce maintenance costs.
Used in Cleaning Agents:
BUTTPARK 80\07-66 is used as a surfactant in the formulation of cleaning agents to improve the wetting and spreading of liquids. This enhances the cleaning efficiency and effectiveness of the agents, leading to better overall performance.
Used in Industrial Coatings:
BUTTPARK 80\07-66 is used as an additive in industrial coatings to enhance the wetting and spreading of the coating on metal surfaces. This results in a more uniform and durable coating, providing better protection and corrosion resistance.
Used in Oil and Gas Industry:
BUTTPARK 80\07-66 is used as a corrosion inhibitor in the oil and gas industry to protect pipelines and other metal infrastructure from the corrosive effects of water and other substances. This helps to maintain the integrity of the infrastructure and prevent leaks and failures.
Used in Automotive Industry:
BUTTPARK 80\07-66 is used as a corrosion inhibitor in automotive applications to protect metal components from oxidation and corrosion, ensuring the longevity and performance of the vehicle. It is also used in the formulation of automotive coatings to provide a durable and protective finish.
Used in Marine Industry:
BUTTPARK 80\07-66 is used as a corrosion inhibitor in marine applications to protect metal components of ships, boats, and offshore structures from the corrosive effects of saltwater and other harsh marine environments. This helps to maintain the structural integrity and performance of these components.
Used in Manufacturing Industry:
BUTTPARK 80\07-66 is used as a corrosion inhibitor and surfactant in various manufacturing processes to protect metal tools, equipment, and machinery from corrosion and improve the efficiency of cleaning and coating processes. This contributes to increased productivity and reduced downtime in manufacturing operations.

Upstream product

• 1607828-44-3 N-acetyl-5-bromo-4-chloroanthranilic acid 
• 5900-55-0 N-(5-chloro-2-methylphenyl)acetamide 
• 1607828-43-2 N-(4-bromo-5-chloro-2-methylphenyl)-acetamide 
• 89-77-0 2-Amino-4-chlorobenzoic acid 

Downstream Products

• 1166378-30-8 6-bromo-7-chloroquinazoline-2,4(1H,3H)-dione 
• 108847-96-7 1-acetyl-5-bromo-6-chloro-1H-indol-3-yl acetate 
• 103029-90-9 N-(4-bromo-5-chloro-2-carboxy)phenylglycine 
• 1036757-11-5 2-amino-5-bromo-4-chlorobenzaldehyde 
• 1036757-10-4 (2-amino-5-bromo-4-chlorophenyl)methanol 
• 1621669-61-1 C₃₈H₁₈BrClN₂ 
• 1621669-62-2 C₃₈H₁₈BrClN₂ 
• 1621669-56-4 C₅₂H₂₆N₂ 
• 1621669-57-5 C₅₂H₂₆N₂ 
• 1621669-63-3 C₅₂H₂₇ClN₂ 
• 1621669-64-4 C₅₂H₂₇ClN₂ 
• 1616955-04-4 (Z)-tert-butyl (2-(4-bromo-5-chloro-2-formylstyryl)phenyl)carbamate 
• 1616954-94-9 tert-butyl (2-((4-bromo-5-chloro-2-(hydroxymethyl)phenyl)ethynyl)phenyl)carbamate 
• 1616954-89-2 (2-((2-aminophenyl)ethynyl)-5-bromo-4-chlorophenyl)methanol 

Relevant academic research and scientific papers

QUINOLINO-PYRROLIDIN-2-ONE DERIVATIVE AND APPLICATION THEREOF

Disclosed are a series of quinolino-pyrrolidin-2-one compounds, and application thereof in preparation of drugs for ATM inhibitor-related diseases. The present disclosure specifically relates to a derivative compound represented by formula (I), tautomers thereof or pharmaceutically acceptable compositions thereof.

5-bromo-6-chloro-3-indolyl caprylate synthesis method

The invention discloses a 5-bromo-6-chloro-3-indolyl caprylate synthesis method, which is characterized in that 4-chloro-2-aminobenzoic acid and N-bromosuccinimide are subjected to a bromination reaction to obtain 5-bromo-4-chloro-2-aminobenzoic acid, 5-b

A 5 - bromo - 4 - chloro - 2 - amino preparation method of acetophenone (by machine translation)

The invention discloses a 5 - bromo - 4 - chloro - 2 - amino acetophenone preparation method, the method comprises the following steps: to 4 - chloro - 2 - aminobenzoic acid as the starting material, the reaction of halide 5 - bromo - 4 - chloro - 2 - ami

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Indoxylic acid esters as convenient intermediates towards indoxyl glycosides

Indoxylic acid methyl and allyl esters with varied halide-substitution patterns were obtained in excellent yields using a scalable route. Phase-transfer glycosylation of these key intermediates was carried out with various glycosyl halides. Subsequent mild silver-mediated decarboxylation followed by Zemplen deacetylation led to indoxyl glycosides in good overall yields. Indoxyl glycosides are well-established and widely used tools for enzyme screening and enzyme-activity monitoring. In the past, their synthesis has been difficult, so this new approach has led to a variety of useful structures. Indoxyl glycosides with varied halide-substitution patterns were synthesized using indoxylic acid esters as key intermediates. Glycosylation under phase-transfer conditions, ester cleavage, and mild decarboxylation led to the indoxyl glycosides in good yields. This approach enables access to a number of different indoxyl compounds. Copyright

Synthesis of DIBAC analogues with excellent SPAAC rate constants

In search for increased reactivity in strain-promoted azide alkyne cycloadditions (SPAAC), the synthesis of new and more reactive cyclooctynes is of pivotal importance. To identify cyclooctynes with enhanced reactivity, without loss of stability, the synthesis and kinetic analysis of new dibenzoazacyclooctyne (DIBAC) analogues were conducted. Starting from iodobenzyl alcohol analogues and ortho-ethynylaniline various substituted dihydrodibenzo[b,f]azocines were produced. Subsequent bromination and elimination proved to be difficult depending on the aromatic substitution pattern, yielding chloro-, bromo-, and methoxy-substituted DIBACs in moderate yield. In the elimination reaction towards nitro- and Br,Cl-DIBAC, the corresponding cyclooctene was obtained instead of the cyclooctyne. Additionally, a dimethoxy-substituted DIBAC analogue was prepared following an alternative route involving light-induced deprotection of a cyclopropenone derivative. In total, four DIBAC analogues were successfully prepared showing excellent rate constants in the SPAAC reaction ranging from 0.45 to 0.9 M-1 s -1, which makes them comparable to the fastest cyclooctynes currently known. This journal is the Partner Organisations 2014.

SUBSTITUTED AZADIBENZOCYCLOOCTYNE COMPOUNDS AND THEIR USE IN METAL-FREE CLICK REACTIONS

The invention relates to a substituted azadibenzocyclooctyne compound according to Formula (5): The invention also relates to a conjugate wherein a substituted azadibenzocyclooctyne according to the invention is conjugated to a label, and to the use of these conjugates for bioorthogonal labeling, imaging or modification of a target molecule, e.g. surface modification. The invention further relates to a method for the modification of a target molecule, wherein a conjugate according to the invention is reacted with a compound comprising a 1,3-dipole or a 1,3-(hetero)diene.

1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The invention relates to imidazoquinolines of formula (I) for use in the treatment of protein kinase dependent diseases; pharmaceutical preparations comprinsing an imidazoquinoline, especially for the treatment of a pretein kinase dependent disease; novel imidazoquinolines; and a process for the preparation of the novel imidazoquinilines.

1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.